Potential Fluorinated Anti‐MRSA Thiazolidinone Derivatives with Antibacterial, Antitubercular Activity and Molecular Docking Studies
MRSA infection is one of the alarming diseases in the current scenario. Identifying newer molecules to treat MRSA infection is of urgent need. In the present study, we have designed fluorinated thiazolidinone derivatives with various aryl/heteroaryl units at 5th position of the thiazolidinone core a...
Gespeichert in:
Veröffentlicht in: | Chemistry & biodiversity 2022-02, Vol.19 (2), p.e202100532-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 2 |
container_start_page | e202100532 |
container_title | Chemistry & biodiversity |
container_volume | 19 |
creator | Kumar, Vasantha Shetty, Premalatha H. S., Arunodaya Chandra K., Sharath Ramu, Ramith Patil, Shashank M. Baliga, Anuradha Rai, Vaishali M. M, Shalini Shenoy Udupi, Vishwanatha Poojary, Vishwanatha Poojary, Boja |
description | MRSA infection is one of the alarming diseases in the current scenario. Identifying newer molecules to treat MRSA infection is of urgent need. In the present study, we have designed fluorinated thiazolidinone derivatives with various aryl/heteroaryl units at 5th position of the thiazolidinone core as promising anti‐MRSA agents. All the compounds were screened for antibacterial activity against four bacterial strains. Among the tested compounds, the halogenated compounds with simple arylidene ring, (5Z)‐5‐[(3‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4b), (5Z)‐5‐[(4‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4c), (5Z)‐5‐[(3‐fluoro‐4‐methylphenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4f) and (5Z)‐5‐[(3,5‐difluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4g) showed excellent activity with MIC 3.125–6.25 μg/mL against S. aureus and P. aeruginosa organism. Furthermore, these potent compounds were screened against MRSA strains, ESKAPE panel organism, and H37Rv mycobacterium strain. Compounds 4c (MIC 0.39 μg/mL), and 4f (MIC 0.39 and 0.79 μg/mL) displayed promising activity against MRSA strains (ATCC and clinical isolates, respectively). The most potent compounds, 4c and 4f eradicated the growth of bacterial colonies in a time‐kill assay indicated that these are bactericidal in nature. The preliminary toxicity study of the potent molecules revealed that these compounds are non‐hemolytic in nature as they did not induce lysis in human RBCs. In addition, the molecular docking and dynamics studies of compounds 4b, 4c, 4f and 4g were carried out on MurB protein of S. aureus (PDB code: 1HSK). Docking results demonstrated remarkable hydrogen bonding interaction with key amino acids ARG310, ASN83, GLY79 and π‐π interactions with TYR149 which confirm the mode of action of the molecules. |
doi_str_mv | 10.1002/cbdv.202100532 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2612392922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629271621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3732-a21a29fb9d1136987da3cf4774dabf1848ccb0488f247e21ccaedff3af2dfea73</originalsourceid><addsrcrecordid>eNqFkTFvFDEQhS0EIiHQUiJLNBTcsR4v593yckcAKRGIBNrVrD0mDr51sL0XHRUVNb-RX4KTC4dEQzUzT988jeYx9lhUU1FV8EL3Zj2FCsrwUsIdti9mAiaiaaq7u17BHnuQ0kXhi97cZ3uybqGtZmqf_XgfMg3ZoedHfgzRDZjJ8HmRfn3_efLhdM7Pzh1-C94ZN4SB-JKiW2N2a0r8yuXzG7ZHnYuO_vnNmMeeoh49Rj7XBXV5w3Ew_CR42srLoL-44TM_zaNxlB6yexZ9oke39YB9PHp1tngzOX73-u1ifjzRUkmYIAiE1vatEULO2kYZlNrWStUGeyuautG6r-qmsVArAqE1krFWogVjCZU8YM-2vpcxfB0p5W7lkibvcaAwpg7Kx2T5DUBBn_6DXoQxDuW6QhVCiRmIQk23lI4hpUi2u4xuhXHTiaq7Tqi7TqjbJVQWntzajv2KzA7_E0kB2i1w5Txt_mPXLQ6Xn_6a_wYRI6DJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2629271621</pqid></control><display><type>article</type><title>Potential Fluorinated Anti‐MRSA Thiazolidinone Derivatives with Antibacterial, Antitubercular Activity and Molecular Docking Studies</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kumar, Vasantha ; Shetty, Premalatha ; H. S., Arunodaya ; Chandra K., Sharath ; Ramu, Ramith ; Patil, Shashank M. ; Baliga, Anuradha ; Rai, Vaishali M. ; M, Shalini Shenoy ; Udupi, Vishwanatha ; Poojary, Vishwanatha ; Poojary, Boja</creator><creatorcontrib>Kumar, Vasantha ; Shetty, Premalatha ; H. S., Arunodaya ; Chandra K., Sharath ; Ramu, Ramith ; Patil, Shashank M. ; Baliga, Anuradha ; Rai, Vaishali M. ; M, Shalini Shenoy ; Udupi, Vishwanatha ; Poojary, Vishwanatha ; Poojary, Boja</creatorcontrib><description>MRSA infection is one of the alarming diseases in the current scenario. Identifying newer molecules to treat MRSA infection is of urgent need. In the present study, we have designed fluorinated thiazolidinone derivatives with various aryl/heteroaryl units at 5th position of the thiazolidinone core as promising anti‐MRSA agents. All the compounds were screened for antibacterial activity against four bacterial strains. Among the tested compounds, the halogenated compounds with simple arylidene ring, (5Z)‐5‐[(3‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4b), (5Z)‐5‐[(4‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4c), (5Z)‐5‐[(3‐fluoro‐4‐methylphenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4f) and (5Z)‐5‐[(3,5‐difluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4g) showed excellent activity with MIC 3.125–6.25 μg/mL against S. aureus and P. aeruginosa organism. Furthermore, these potent compounds were screened against MRSA strains, ESKAPE panel organism, and H37Rv mycobacterium strain. Compounds 4c (MIC 0.39 μg/mL), and 4f (MIC 0.39 and 0.79 μg/mL) displayed promising activity against MRSA strains (ATCC and clinical isolates, respectively). The most potent compounds, 4c and 4f eradicated the growth of bacterial colonies in a time‐kill assay indicated that these are bactericidal in nature. The preliminary toxicity study of the potent molecules revealed that these compounds are non‐hemolytic in nature as they did not induce lysis in human RBCs. In addition, the molecular docking and dynamics studies of compounds 4b, 4c, 4f and 4g were carried out on MurB protein of S. aureus (PDB code: 1HSK). Docking results demonstrated remarkable hydrogen bonding interaction with key amino acids ARG310, ASN83, GLY79 and π‐π interactions with TYR149 which confirm the mode of action of the molecules.</description><identifier>ISSN: 1612-1872</identifier><identifier>EISSN: 1612-1880</identifier><identifier>DOI: 10.1002/cbdv.202100532</identifier><identifier>PMID: 34929067</identifier><language>eng</language><publisher>Switzerland: Wiley Subscription Services, Inc</publisher><subject>Amino acids ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; anti-MRSA ; Antibacterial activity ; Antitubercular Agents - pharmacology ; Clinical isolates ; Drug resistance ; Fluorination ; Halogenated compounds ; Humans ; Hydrogen bonding ; Infections ; Lysis ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Mode of action ; Molecular docking ; Molecular Docking Simulation ; MurB docking study ; Staphylococcus aureus ; Strains (organisms) ; Structure-Activity Relationship ; thiazolidinone ; time kill kinetics ; Toxicity</subject><ispartof>Chemistry & biodiversity, 2022-02, Vol.19 (2), p.e202100532-n/a</ispartof><rights>2021 Wiley‐VHCA AG, Zurich, Switzerland</rights><rights>2021 Wiley-VHCA AG, Zurich, Switzerland.</rights><rights>2022 Wiley‐VHCA AG, Zurich, Switzerland</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3732-a21a29fb9d1136987da3cf4774dabf1848ccb0488f247e21ccaedff3af2dfea73</citedby><cites>FETCH-LOGICAL-c3732-a21a29fb9d1136987da3cf4774dabf1848ccb0488f247e21ccaedff3af2dfea73</cites><orcidid>0000-0001-6725-3289 ; 0000-0002-8915-5847</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcbdv.202100532$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcbdv.202100532$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34929067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Vasantha</creatorcontrib><creatorcontrib>Shetty, Premalatha</creatorcontrib><creatorcontrib>H. S., Arunodaya</creatorcontrib><creatorcontrib>Chandra K., Sharath</creatorcontrib><creatorcontrib>Ramu, Ramith</creatorcontrib><creatorcontrib>Patil, Shashank M.</creatorcontrib><creatorcontrib>Baliga, Anuradha</creatorcontrib><creatorcontrib>Rai, Vaishali M.</creatorcontrib><creatorcontrib>M, Shalini Shenoy</creatorcontrib><creatorcontrib>Udupi, Vishwanatha</creatorcontrib><creatorcontrib>Poojary, Vishwanatha</creatorcontrib><creatorcontrib>Poojary, Boja</creatorcontrib><title>Potential Fluorinated Anti‐MRSA Thiazolidinone Derivatives with Antibacterial, Antitubercular Activity and Molecular Docking Studies</title><title>Chemistry & biodiversity</title><addtitle>Chem Biodivers</addtitle><description>MRSA infection is one of the alarming diseases in the current scenario. Identifying newer molecules to treat MRSA infection is of urgent need. In the present study, we have designed fluorinated thiazolidinone derivatives with various aryl/heteroaryl units at 5th position of the thiazolidinone core as promising anti‐MRSA agents. All the compounds were screened for antibacterial activity against four bacterial strains. Among the tested compounds, the halogenated compounds with simple arylidene ring, (5Z)‐5‐[(3‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4b), (5Z)‐5‐[(4‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4c), (5Z)‐5‐[(3‐fluoro‐4‐methylphenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4f) and (5Z)‐5‐[(3,5‐difluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4g) showed excellent activity with MIC 3.125–6.25 μg/mL against S. aureus and P. aeruginosa organism. Furthermore, these potent compounds were screened against MRSA strains, ESKAPE panel organism, and H37Rv mycobacterium strain. Compounds 4c (MIC 0.39 μg/mL), and 4f (MIC 0.39 and 0.79 μg/mL) displayed promising activity against MRSA strains (ATCC and clinical isolates, respectively). The most potent compounds, 4c and 4f eradicated the growth of bacterial colonies in a time‐kill assay indicated that these are bactericidal in nature. The preliminary toxicity study of the potent molecules revealed that these compounds are non‐hemolytic in nature as they did not induce lysis in human RBCs. In addition, the molecular docking and dynamics studies of compounds 4b, 4c, 4f and 4g were carried out on MurB protein of S. aureus (PDB code: 1HSK). Docking results demonstrated remarkable hydrogen bonding interaction with key amino acids ARG310, ASN83, GLY79 and π‐π interactions with TYR149 which confirm the mode of action of the molecules.</description><subject>Amino acids</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>anti-MRSA</subject><subject>Antibacterial activity</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Clinical isolates</subject><subject>Drug resistance</subject><subject>Fluorination</subject><subject>Halogenated compounds</subject><subject>Humans</subject><subject>Hydrogen bonding</subject><subject>Infections</subject><subject>Lysis</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Mode of action</subject><subject>Molecular docking</subject><subject>Molecular Docking Simulation</subject><subject>MurB docking study</subject><subject>Staphylococcus aureus</subject><subject>Strains (organisms)</subject><subject>Structure-Activity Relationship</subject><subject>thiazolidinone</subject><subject>time kill kinetics</subject><subject>Toxicity</subject><issn>1612-1872</issn><issn>1612-1880</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkTFvFDEQhS0EIiHQUiJLNBTcsR4v593yckcAKRGIBNrVrD0mDr51sL0XHRUVNb-RX4KTC4dEQzUzT988jeYx9lhUU1FV8EL3Zj2FCsrwUsIdti9mAiaiaaq7u17BHnuQ0kXhi97cZ3uybqGtZmqf_XgfMg3ZoedHfgzRDZjJ8HmRfn3_efLhdM7Pzh1-C94ZN4SB-JKiW2N2a0r8yuXzG7ZHnYuO_vnNmMeeoh49Rj7XBXV5w3Ew_CR42srLoL-44TM_zaNxlB6yexZ9oke39YB9PHp1tngzOX73-u1ifjzRUkmYIAiE1vatEULO2kYZlNrWStUGeyuautG6r-qmsVArAqE1krFWogVjCZU8YM-2vpcxfB0p5W7lkibvcaAwpg7Kx2T5DUBBn_6DXoQxDuW6QhVCiRmIQk23lI4hpUi2u4xuhXHTiaq7Tqi7TqjbJVQWntzajv2KzA7_E0kB2i1w5Txt_mPXLQ6Xn_6a_wYRI6DJ</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Kumar, Vasantha</creator><creator>Shetty, Premalatha</creator><creator>H. S., Arunodaya</creator><creator>Chandra K., Sharath</creator><creator>Ramu, Ramith</creator><creator>Patil, Shashank M.</creator><creator>Baliga, Anuradha</creator><creator>Rai, Vaishali M.</creator><creator>M, Shalini Shenoy</creator><creator>Udupi, Vishwanatha</creator><creator>Poojary, Vishwanatha</creator><creator>Poojary, Boja</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6725-3289</orcidid><orcidid>https://orcid.org/0000-0002-8915-5847</orcidid></search><sort><creationdate>202202</creationdate><title>Potential Fluorinated Anti‐MRSA Thiazolidinone Derivatives with Antibacterial, Antitubercular Activity and Molecular Docking Studies</title><author>Kumar, Vasantha ; Shetty, Premalatha ; H. S., Arunodaya ; Chandra K., Sharath ; Ramu, Ramith ; Patil, Shashank M. ; Baliga, Anuradha ; Rai, Vaishali M. ; M, Shalini Shenoy ; Udupi, Vishwanatha ; Poojary, Vishwanatha ; Poojary, Boja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3732-a21a29fb9d1136987da3cf4774dabf1848ccb0488f247e21ccaedff3af2dfea73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Amino acids</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>anti-MRSA</topic><topic>Antibacterial activity</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Clinical isolates</topic><topic>Drug resistance</topic><topic>Fluorination</topic><topic>Halogenated compounds</topic><topic>Humans</topic><topic>Hydrogen bonding</topic><topic>Infections</topic><topic>Lysis</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Mode of action</topic><topic>Molecular docking</topic><topic>Molecular Docking Simulation</topic><topic>MurB docking study</topic><topic>Staphylococcus aureus</topic><topic>Strains (organisms)</topic><topic>Structure-Activity Relationship</topic><topic>thiazolidinone</topic><topic>time kill kinetics</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Vasantha</creatorcontrib><creatorcontrib>Shetty, Premalatha</creatorcontrib><creatorcontrib>H. S., Arunodaya</creatorcontrib><creatorcontrib>Chandra K., Sharath</creatorcontrib><creatorcontrib>Ramu, Ramith</creatorcontrib><creatorcontrib>Patil, Shashank M.</creatorcontrib><creatorcontrib>Baliga, Anuradha</creatorcontrib><creatorcontrib>Rai, Vaishali M.</creatorcontrib><creatorcontrib>M, Shalini Shenoy</creatorcontrib><creatorcontrib>Udupi, Vishwanatha</creatorcontrib><creatorcontrib>Poojary, Vishwanatha</creatorcontrib><creatorcontrib>Poojary, Boja</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Chemistry & biodiversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Vasantha</au><au>Shetty, Premalatha</au><au>H. S., Arunodaya</au><au>Chandra K., Sharath</au><au>Ramu, Ramith</au><au>Patil, Shashank M.</au><au>Baliga, Anuradha</au><au>Rai, Vaishali M.</au><au>M, Shalini Shenoy</au><au>Udupi, Vishwanatha</au><au>Poojary, Vishwanatha</au><au>Poojary, Boja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential Fluorinated Anti‐MRSA Thiazolidinone Derivatives with Antibacterial, Antitubercular Activity and Molecular Docking Studies</atitle><jtitle>Chemistry & biodiversity</jtitle><addtitle>Chem Biodivers</addtitle><date>2022-02</date><risdate>2022</risdate><volume>19</volume><issue>2</issue><spage>e202100532</spage><epage>n/a</epage><pages>e202100532-n/a</pages><issn>1612-1872</issn><eissn>1612-1880</eissn><abstract>MRSA infection is one of the alarming diseases in the current scenario. Identifying newer molecules to treat MRSA infection is of urgent need. In the present study, we have designed fluorinated thiazolidinone derivatives with various aryl/heteroaryl units at 5th position of the thiazolidinone core as promising anti‐MRSA agents. All the compounds were screened for antibacterial activity against four bacterial strains. Among the tested compounds, the halogenated compounds with simple arylidene ring, (5Z)‐5‐[(3‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4b), (5Z)‐5‐[(4‐chloro‐2‐fluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4c), (5Z)‐5‐[(3‐fluoro‐4‐methylphenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4f) and (5Z)‐5‐[(3,5‐difluorophenyl)methylidene]‐2‐[(1,3‐thiazol‐2‐yl)amino]‐1,3‐thiazol‐4(5H)‐one (4g) showed excellent activity with MIC 3.125–6.25 μg/mL against S. aureus and P. aeruginosa organism. Furthermore, these potent compounds were screened against MRSA strains, ESKAPE panel organism, and H37Rv mycobacterium strain. Compounds 4c (MIC 0.39 μg/mL), and 4f (MIC 0.39 and 0.79 μg/mL) displayed promising activity against MRSA strains (ATCC and clinical isolates, respectively). The most potent compounds, 4c and 4f eradicated the growth of bacterial colonies in a time‐kill assay indicated that these are bactericidal in nature. The preliminary toxicity study of the potent molecules revealed that these compounds are non‐hemolytic in nature as they did not induce lysis in human RBCs. In addition, the molecular docking and dynamics studies of compounds 4b, 4c, 4f and 4g were carried out on MurB protein of S. aureus (PDB code: 1HSK). Docking results demonstrated remarkable hydrogen bonding interaction with key amino acids ARG310, ASN83, GLY79 and π‐π interactions with TYR149 which confirm the mode of action of the molecules.</abstract><cop>Switzerland</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34929067</pmid><doi>10.1002/cbdv.202100532</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-6725-3289</orcidid><orcidid>https://orcid.org/0000-0002-8915-5847</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1612-1872 |
ispartof | Chemistry & biodiversity, 2022-02, Vol.19 (2), p.e202100532-n/a |
issn | 1612-1872 1612-1880 |
language | eng |
recordid | cdi_proquest_miscellaneous_2612392922 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Amino acids Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - pharmacology anti-MRSA Antibacterial activity Antitubercular Agents - pharmacology Clinical isolates Drug resistance Fluorination Halogenated compounds Humans Hydrogen bonding Infections Lysis Microbial Sensitivity Tests Minimum inhibitory concentration Mode of action Molecular docking Molecular Docking Simulation MurB docking study Staphylococcus aureus Strains (organisms) Structure-Activity Relationship thiazolidinone time kill kinetics Toxicity |
title | Potential Fluorinated Anti‐MRSA Thiazolidinone Derivatives with Antibacterial, Antitubercular Activity and Molecular Docking Studies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A58%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20Fluorinated%20Anti%E2%80%90MRSA%20Thiazolidinone%20Derivatives%20with%20Antibacterial,%20Antitubercular%20Activity%20and%20Molecular%20Docking%20Studies&rft.jtitle=Chemistry%20&%20biodiversity&rft.au=Kumar,%20Vasantha&rft.date=2022-02&rft.volume=19&rft.issue=2&rft.spage=e202100532&rft.epage=n/a&rft.pages=e202100532-n/a&rft.issn=1612-1872&rft.eissn=1612-1880&rft_id=info:doi/10.1002/cbdv.202100532&rft_dat=%3Cproquest_cross%3E2629271621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2629271621&rft_id=info:pmid/34929067&rfr_iscdi=true |